| Hector Guzman Fontanez Sr, | |
|
Carr.13 Kilo.3 Hec.4 Bario Palohincado Sector Pinonas, Barranquitas, PR 00794 | |
| (787) 857-7582 | |
| Not Available |
| Full Name | Hector Guzman Fontanez Sr |
|---|---|
| Gender | Male |
| Speciality | Licensed Practical Nurse |
| Location | Carr.13 Kilo.3 Hec.4 Bario Palohincado Sector Pinonas, Barranquitas, Puerto Rico |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1669886412 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | 72012 (Puerto Rico) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Hector Guzman Fontanez Sr, Po Box 404, Barranquitas, PR 00794-0404 Ph: () - | Hector Guzman Fontanez Sr, Carr.13 Kilo.3 Hec.4 Bario Palohincado Sector Pinonas, Barranquitas, PR 00794 Ph: (787) 857-7582 |
News Archive
"In advance of the XIX International AIDS Conference - AIDS 2012 - CSIS celebrated the release of the special supplement of the Journal of AIDS focused on PEPFAR" with an event organized in cooperation with the Office of the Global AIDS Coordinator (OGAC)," the Center for Strategic & International Studies' (CSIS) "Smart Global Health" blog reports.
Chemical Abstracts Service, the world's authority for chemical information, announced today a landmark five-year agreement for SciFinder, the choice for chemistry research, with AstraZeneca, a leading biopharmaceutical company specializing in the discovery, development, manufacturing and marketing of prescription medicines. The long-term agreement guarantees AstraZeneca researchers access to the most accurate, comprehensive and current research, available only in SciFinder.
Most parents are all too familiar with the equation school + kids = sick days. With more than 200 cold viruses it's no wonder parents feel like they are fighting a losing battle when it comes to keeping their kids healthy.
An examination of the potential interaction between pharmaceutical companies and the U.S. Food and Drug Administration (FDA) to discuss future studies finds that one-quarter of recent new drug approvals occurred without any meeting, and when such meetings occurred, pharmaceutical companies did not comply with one-quarter of the recommendations made by the FDA regarding study design or primary outcome, according to a study in the November 26 issue of JAMA.
For many patients with advanced breast cancer, the cancer drug Herceptin (trastuzumab) has offered new hope when traditional cancer drugs failed to work, shrinking tumors and sending some patients into remission.
› Verified 2 days ago